

Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health
Advisory Board on Radiation and Worker Health (ABRWH)
Subcommittee on Dose Reconstruction Reviews
Meeting Minutes

June 4, 2024

Summary Proceedings

The meeting of the Subcommittee on Dose Reconstruction Reviews convened via teleconference at 11:05 a.m. Eastern Daylight Time (EDT), Dr. David Kotelchuck, Chair, presiding.

Attendees

Members

David Kotelchuck, Chair
Josie Beach, Member
Bradley P. Clawson, Member
Arthur Frank, Member
Loretta R. Valerio, Member

Non-Members

Rashaun Roberts, Designated Federal Official
Bob Barton, SC&A
Kathy Behling, SC&A
Ron Buchanan, SC&A
Rose Gogliotti, SC&A
Maria Holsberger, HHS
Alek Kranbuhl, DCAS
Megan Lobaugh, DCAS
Amy Mangel, SC&A
Lori Marion-Moss, DCAS
Pat McCloskey, ORAU Team
Beth Rolfes, DCAS
LaVon Rutherford, DCAS
Mutti Sharfi, ORAUT Team

Scott Siebert, ORAU Team
Cheri Smyser
Matthew Smith, ORAU Team
Brant Ullsh, DCAS

Roll Call/Welcome - Dr. Rashaun Roberts, DFO

Dr. Rashaun Roberts opened the meeting at 11:05 a.m., EDT. A roll call of all Subcommittee members confirmed that a quorum was present. The quorum was maintained throughout the meeting. Subcommittee members, federal staff, and contractors declared any conflicts of interest during roll call.

Issues Resolution from Set 31

Dr. Kotelchuck noted that the Cybersecurity Modernization Initiative had severely affected the work of the Subcommittee, and that this is their first meeting in two years. He then turned to Rose Gogliotti, SC&A, to lead the discussion of Set 31 dose reconstruction reviews.

Ms. Gogliotti began by refreshing Subcommittee members of how SC&A classifies their review findings into type 1 and type 2 findings. Type 1 findings are those where SC&A and DCAS have arrived at some type of agreement. Type 2 findings are those where SC&A and DCAS have not yet come to agreement. Subcommittee members may have questions and comments about both types of findings, and member comments may result in additional investigation by SC&A and DCAS on both types of findings.

Ms. Gogliotti then described the type 1 findings and observations that SC&A had identified in their Set 31 review of dose reconstructions. The Subcommittee agreed to close all but one of those. The one that was not closed was placed in abeyance until DCAS and ORAU Team develop guidance for reconstructing medical X-ray exposures for workers who move between Oak Ridge covered facilities. Additionally, the Subcommittee noted that one of the findings, when corrected, would change the claim from compensable to non-compensable. No further action will be taken on the claim. The Subcommittee closed the finding but will mention this outcome in a future report to the Secretary.

Next Ms. Gogliotti described the Type 2 findings and observations from Set 31. A limited number of observations were closed as a result of the discussion. The majority of findings and observations remained in progress, as the Subcommittee, SC&A, DCAS, and ORAU Team agreed on additional information to exchange. Two findings were transferred to the Hanford Work Group, one finding was transferred to the Metals & Controls Work Group, and two observations were transferred to the Subcommittee for Procedures Reviews.

The next set of dose reconstruction reviews, Set 32, has been completed by SC&A. DCAS and ORAUT Team are in the process of preparing responses. The Board Review

System (BRS), which was disabled during the Cybersecurity Modernization Initiative, has recently been replaced by a new version. DCAS and ORAU Team intend to place responses for Set 32 findings and observations in BRS to facilitate future Subcommittee discussions. Ms. Gogliotti will arrange to provide training to Subcommittee members, and perhaps all ABRWH members, on accessing and using the new BRS.

Issues Resolution Tab 585 Set 29 (Pantex)

SC&A's finding 2 for this case, which questioned the dose conversion factor that was used, was previously discussed at the Subcommittee's January 2022 meeting. The reference that was used to develop the dose conversion factor had been cancelled at the time the dose reconstruction was reviewed. The Subcommittee tasked SC&A to review the cancelled document to confirm that the dose reconstruction factor was appropriate. Amy Mangel, SC&A, reported that they had obtained a copy of the cancelled document, and had confirmed that the dose reconstruction factor complied with the guidance in that document. Consequently, the Subcommittee closed this finding.

Report and further discussion on changes to selection criteria

Rose Gogliotti, SC&A, led a discussion about the types of claimants whose dose reconstructions are being selected for review by the Subcommittee. At the April 2022, meeting of the full Advisory Board, Dr. Kotelchuck had recommended changing the selection criteria for dose reconstruction review in order to increase the number of female claimants whose dose reconstructions are reviewed. The Subcommittee had recognized that only about 10% of reviewed dose reconstructions were for female energy employees, even though it appears that about 27% of claimants are female. The full Board agree with the recommendation, so the Subcommittee decided to attempt to select a higher proportion of female claims for future reviews. Despite this, the most recent set of reviewed claims, Set 33, contained only 3 female claimants out of 30 claims selected for review. This appears to be due to the limited number of female claims that fall into the Subcommittee's other selection criteria, such as age of the claim, and a POC close to the decision point of 50%. The Subcommittee asked DCAS and SC&A to begin the selection process for Set 34 and consider expanding the POC selection criteria to 40% to 55% in the hope of increasing the number of female claims available for review.

Next Meeting

The Subcommittee discussed scheduling the next meeting. The date of the next meeting will depend on when DCAS and ORAU Team provide responses to SC&A's comments from their reviews of the dose reconstructions in Set 32. DCAS and ORAU Team will try to provide an estimate for when they will finalize their responses and inform Dr. Roberts. She will then contact Subcommittee members to schedule the next

meeting a suitable time later to allow SC&A to review the responses and prepare for the meeting.

Meeting Adjourned

Dr. Kotelchuck adjourned the meeting at 4:44 p.m. EDT.